Biomedical subjects
Publications and source records attributed to G D Lowe.
A severely affected haemophilic boy became tetraparetic as a result of a spontaneously occurring intraspinal haematoma. Myelography defined the extent of the lesion and showed it to be extradural in site. Infusion of large doses of factor VIII concentrate led to dramatic improvement and avoided the need to operate.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
In a randomised double-blind controlled trial we have assessed the use of ancrod ('Arvin') in the prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip replacement surgery. Thirty-five patients received daily subcutaneous injections of ancrod and 38 patients received saline injections. DVT was detected by bilateral ascending venography (67 patients) 7-19 days after surgery. The frequency of major femoral DVT (greater than or equal to 5 cm long) was significantly reduced from 18 thrombi in the limbs of the placebo group to 5 in the ancrod group (p less than 0.01). The overall frequency of thrombi including calf DVT was not significantly different between the two groups. Four patients within the ancrod group had evidence of wound bleeding, compared with 2 placebo patients. One patient had a bleeding event which was considered severe enough to require cessation of ancrod injections.
Red cell aggregation may be higher in diabetic patients and may predispose to cardiovascular disease. Red cell aggregation was measured by a simple photometric method in 122 diabetic patients and 100 matched control subjects, to determine its relationship to cardiovascular risk factors. Red cell aggregation was significantly increased in both Type 1 (4.3 +/- 1.3 vs 3.4 +/- 1.2, p < 0.002) and Type 2 diabetic patients (5.5 +/- 1.5 vs 3.2 +/- 1.3, p < 0.0001). In all diabetic patients aggregation correlated with triglycerides, VLDL, and inversely with HDL and in Type 2 diabetic patients also with body mass index, hypertension, and inversely with duration of diabetes. On multiple regression analysis, triglycerides and body mass index showed an independent association with red cell aggregation and in Type 2 diabetic patients smoking was also associated with increased red cell aggregation. It is concluded that increased red cell aggregation may be one mechanism by which some cardiovascular risk factors could promote cardiovascular disease in diabetes.
A questionnaire was sent to 508 consultants in Scotland likely to encounter deep vein thrombosis and pulmonary embolism to assess their current standard practice in diagnosis and treatment of these disorders. Replies were received from 358 (70.5%). In deep vein thrombosis 47% and in pulmonary embolism 33% of consultants usually depended on clinical observation alone for diagnosis. In deep vein thrombosis 37% used venography to supplement clinical diagnosis and in pulmonary embolism 13% used angiography and 53% used isotopic scanning. Almost all consultants treated deep vein thrombosis (95%) and pulmonary embolism (99%) with anticoagulants. Most consultants (81%) gave heparin by intravenous infusion. Although many consultants gave intravenous heparin for more than three days (49.5% in deep vein thrombosis and 61% in pulmonary embolism), 25% of these consultants did not use any laboratory monitoring of heparin's effect. Large numbers of consultants gave warfarin for more than three months (20% in deep vein thrombosis and 47% in pulmonary embolism). There was a significant tendency to give heparin (p less than 0.01) and warfarin (p less than 0.001) for longer periods in pulmonary embolism than in deep vein thrombosis. This survey shows a widely varying practice and underlines the need for further controlled studies to provide clear guidance in the management of deep vein thrombosis and pulmonary embolism.
Atherothrombosis is a systemic disease, hence it is difficult to prove the specificity of haemostasis abnormality for any single vascular phenotype. Associations between haemostatic variables and any given phenotype, e.g. (vascular) dementia, should be interpreted with caution, given the overlaps of vascular disease phenotypes, risk factors, and haemostatic variables.
Fifty-two patients with chronic renal failure undergoing hospital haemodialysis were given a single bolus dose of tinzaparin (Innohep, Leo Laboratories, UK) into the arterial side of the dialyser, for up to 43 consecutive dialyses. The mean tinzaparin dose at the beginning was 2,139 IU anti-Xa and at the end 2,186 IU anti-Xa. Overall, tinzaparin proved a satisfactory anticoagulant for 1,370 (96.0%) out of 1,427 dialyses. Significant clot formation was prevented in 1,326 (92.8%) out of 1,429 dialyses. The clinically effective dose was associated with a mean plasma anti-Xa activity 1 h after dosing of 0.4 IU/ml and suppressed fibrinopeptide A formation for up to 4 h. Bleeding, from the skin or mucous membranes, was recorded at 27 (1.9%) of 1,408 dialyses. Prolonged fistula bleeding on completion of dialysis was recorded on only 20 occasions. Other haemorrhagic events included haematemesis, bruising and subconjunctival haemorrhage (each in 1 patient) and epistaxis (2 patients). Three patients died during the study of causes considered unrelated to tinzaparin therapy, myocardial infarction (2 patients) and multiple myeloma. Other adverse events reported included vomiting (3 patients) and hypotension (3 patients). Three patients ceased treatment due to haematemesis, prolonged bleeding from fistula puncture and thrombosis of the arteriovenous access, respectively. A small, but statistically significant, increase within the normal reference range was recorded in the mean values for aspartate aminotransferase and alanine aminotransferase.
Explore the source record for details and available documents.
The influence of hematocrit on red blood cell aggregation was investigated using a modified automated Myrenne Aggregometer System. Hematocrit values ranged from 20-70% at 10% increments, and were produced by resuspending washed red cells in autologous plasma. The Myrenne System produced seven kinetic parameters of red cell aggregation. The results indicate that hematocrit (Hct) had a strong and nonlinear effect on erythrocyte aggregability. At both low and high hematocrit, the aggregation intensity (AI) tends to decrease, reaching a plateau at 40% hematocrit. The disaggregation shear rate demonstrates an exponential relationship as In gamma TMIN = 3.29-0.0837 Hct. Time constants of the aggregation process such as T1/2, TSLOW and TFAST were rather inconsistent. The increase of hematocrit increased the rate of the fast phase aggregation and slightly slowed the secondary aggregation.
Monitoring of the influence of cardiopulmonary bypass (CPB) on hematologic parameters is relevant to an improved understanding of the pathophysiology produced, as well as for the development of improved methods. The selection of suitable parameters is highly important. In this study, both contact phase activation and leukocyte response have been studied. Contact activation was determined by a novel assay for the measurement of Factor XII activity (FXIIA), and leukocyte response was measured by the release of granulocyte elastase. Five patients undergoing elective coronary artery surgery using a bubble oxygenator and pulsatile perfusion were studied. A notable feature of this study was the gradual increase of FXIIA during the study period, with granulocyte elastase levels following a similar pattern. Both FXIIA and granulocyte elastase are appropriate parameters for monitoring CPB, and could be useful in studying alternative bypass procedures and antithrombotic agents.